glp-1 ibd 🚨 RA use in is rising fast In this 14-month repeated survey of patients with IBD: 📈 GLP-1 RA use rose 5-fold ⚖️ Median BMI fell from 35.3 → 31.2 Role of glucagon-like peptides in

Building upon the growing recognition of cardiometabolic organ protection as a central therapeutic goal, incretin-based therapies have reshaped the management of type 2 diabetes and obesity, extending their clinical relevance far beyond glycemic control

No path to weight loss is complete without an understanding of your body's nutrient needs and how best to meet them

Use a New Needle Each Time: Reusing needles can dull them and introduce bacteria

About the company Eli Lilly & Co discovers, develops, manufactures, and sells pharmaceutical products

Fang, Y

Early Evidence In the latest GLP-1 study 2025 , orforglipron showed early promise for adults with obesity and those living with type 2 diabetes, especially at the highest evaluated dose